Immune recognition of BoNTs A and B: How anti-toxin antibodies obstruct toxin action
Association of botulinum neurotoxins with synaptic vesicle protein complexes
Botulinum neurotoxin interactions with substrate
Capture assay for Botulinum Neurotoxin Type A utilizing the receptor protein SV2c
C-terminal fragment of tetanus toxin heavy chain modulates sphingomyelinase activity in neuronal preparations
Identification of the fibroblast growth factor receptor FGFR3 as a component of the receptor complex for Botulinum Neurotoxin Type A
A novel function of botulinum toxin-associated proteins: The HA component disrupts intestinal epithelial intercellular junctions to increase toxin absorption
Production of mutants in the N-terminal region of the Hc-TeTx fragment on the basis of similarities with nerve growth factor. Evaluation of the viability on stressed cultured neurons
Translocation of the light chain protease by the heavy chain protein-conducting channel
Binding of botulinum neurotoxin A to the plasma membrane
Characterising and exploiting the binding of botulinum neurotoxins to their neuronal receptors
The mechanism of axonal transport of tetanus toxin in vivo and in vitro
Surface plasmon resonance analysis of botulinum neurotoxin binding for lipid receptors
An assay for the botulinum toxins that requires functional binding and catalytic domains within the neurotoxin
DARET assays of BoNT proteolytic activity with a fully recombinant substrate
Synaptic vesicle cycle
Botulinum toxin blocks neurotransmitter release from somata of rat neuropathic trigeminal ganglion neurons
The effect of peripheral administration of botulinum toxin type A in rats with neuropathic pain
Studies with botulinum toxins in excitatory and inhibitory neurons
Substrate recognition mechanism of VAMP/synaptobrevin cleaving clostridial neurotoxins
Relevance of the crystal vs. solution structure of botulinum neurotoxin for understanding its mechanism of action and development of inhibitors
Issues in therapeutic development against botulinum neurotoxins (BONT)
Human botulism immune globulin for the treatment of infant botulism: The first four years post-licensure
Analgesic effects of Botulinum toxin A in an inflammatory pain model in rats: Comparison of Dysport® and Botox®; synergistic interaction with morphine
Xeomin® displays lower potency and is neutralized by anti-BOTOX® antibodies
An histological assessment of diffusion of different botulinum neurotoxin type A formulations injected in the mice leg
Equivalent potency of Xeomin® and BOTOX®
Dissociation of the 900 kDa neurotoxin complex from C. botulinum under physiological conditions
Analgesic properties of botulinum toxin type A (Dysport®) in paclitaxel-induced peripheral neuropathy in rats
A sensitive and robust Western Blot cell-based assay to measure the activity of botulinum neurotoxin serotype A
Xeomin® is free from complexing proteins
Reductive therapeutic strategy to prevent BONT intoxication
Fully active recombinant Bont/E purified from E. coli in high yield
Incidence of neutralizing antibody formation to botulinum toxin type A in patients with primary axillary hyperhidrosis: A pooled analysis of 4 prospective clinical trials
The therapeutic window in rats of botulinum neurotoxin subtype A2 is wider than that of subtype A1, regardless of the presence of nontoxic proteins
Xeomin® is stable without refrigeration: Complexing proteins are not required for stability of botulinum neurotoxin type A preparations
Secondary cleavage of a fluorescently labeled SNAP-25 substrate by Xeomin® drug product
Small molecule therapeutic approaches for the treatment of botulinum neurotoxins A and B intoxication
A neuronal cell-based assay for highly sensitive detection of pharmaceutical preparations of BONT/A and patient neutralizing serum antibodies
Development of a novel non-formaldehyde botulinum toxoid inducing high levels of neutralising antibody
Long-term-repeated intramuscular injection of botulinum toxin type A complex vs. complex-free toxin; comparisons of pharmacological efficacy and immunogenecity
A comparative study of botulinum neurotoxin preparations; Botox®, Dysport®, and Neuronox® using digit abduction scoring assay
Botulinum type A2 neurotoxin (150 kDa) is stronger than type A1 progenitor toxin (900 kDa) in the inhibition activity of neuromuscular transmission of isolated mouse phrenic nerve-hemidiaphragm
Kinetics of the onset of paralysis produced by type A botulinum neurotoxin
Multiple events triggered by the use of botulinum neurotoxins at the vertebrate neuromuscular junction
Comparison of immunogenicity between LL toxin from subtype A1 and NTX from subtype A2
Development of a Botulinum Neurotoxin animal inhalation model and evaluation of small molecule therapeutics for medical countermeasure
Design of fluorogenic substrates for botulinum toxin A quantification and identification of a novel cooperative exosite for substrate binding
Therapeutics which accelerate degradation BoNT/A LC within neurons
Botulinum toxin injection into the trapezius muscle of cynomolgus monkeys: Comparison of serotype A with B
Migration of type A botulinum toxin in vivo is not related to the size of the toxin complex
Counterfeit botulinum toxins—A serious risk to patient safety
Development of a multi-step approach for the detection of neutralising antibodies to botulinum toxin Type A
Optimising effects of botulinum toxin by post-injection activity
NTX, highly purified botulinum neurotoxin product, is less likely to spread
Pharmacologic effects of repeated administration of Myobloc® (botulinum toxin type B) on rat salivary gland
Pharmacologic effects of myobloc® (botulinum toxin type B, BoNT/B) on rat salivary gland: A dose-ranging study
Activation time-course and in vivo pharmacological analysis of native BoNT/E
Somatosensory temporal discrimination in patients with blepharospasm
Biological effects of un-nicked BoNT/B toxin
Characterization of time-dependent enzymatic profiles under various liquid conditions for 150 and 900 kDa botulinum Type-A neurotoxins
Quantification of potency of neutralizing antibody to botulinum toxin by measuring the compound muscle action potential (CMAP)
Efficacy of botulinum neurotoxin subtype A2 in rats producing neutralizing antibody against botulinum neurotoxin subtype A1
Comparison of diffusive of botulinum toxin preparations in the grip strength of rat
Biological activity of Dysport® and Botox® in the human EDB muscle: A double-blind, randomized, dose-ranging study
Adult upper limb spasticity
A shot of myobloc: An answer to 25-year battle with Tics?
Neurobloc®/myobloc®: Unique features and findings
Clinical safety of NT 201 (Xeomin®): A meta-analysis
Botulinum Toxin Type B clinical safety in cervical dystonia following up to 4 years of treatment
Botulinum toxin therapy for laryngeal dystonia and other hyperfunctional laryngeal disorders
Botulinum toxin in Hallervorden–spatz syndrome
Ultrasound guided intramuscular injection of botulinum toxin A in a patient with writer's cramp—A case report
Clinically meaningful differences of the Ashworth Scale in patients with chronic post-stroke upper limb spasticity treated with botulinum neurotoxin type A (botox®)
Botulinum toxins for the treatment of cervical dystonia
A case of PKAN treated with botulinum toxin A
Importance of botulinum toxin in symptomatic treatment of Wilson's disease
Tic, tremors and other hyperkinesias
EMG changes in myofascial trigger point after type A botulinum toxin
Patient registry of outcomes in spasticity care
Characteristics of long-term botulinum neurotoxin injections and continuation of care at a major medical center
Improvement in ADL care delivery after treatment with botulinum toxin type A (BOTOX®) in patients with profound ID and spasticity: Results from a blinded outcomes study
Safety of Botulinum toxin a in cerebral palsy
Generalized dystonia in a patient with bilateral striopallidodentate calcinosis responsive to botulinum toxin type A
Focal hand dystonia
Treatment of heterogeneous forms of cervical dystonia with botulinum toxin A (500 U dysport®)—First aspects of a multicentre open study
The approach to rehabilitation in post-traumatic spasticity
Disease-oriented approach to botulinum toxin use
Efficacy of NT 201 (Xeomin®) in focal dystonia
Experience with A2NTX in dystonia and spasticity
Long-term treatment with botulinum toxin type A in hemifacial spasm
Botulinum toxin treatment for pain in atypical parkinsonism
Effect of the C-terminal chain of tetanus toxin on the motor behaviors in unilateral MPP+-lesioned rats
Long-term treatment of spasticity with botulinum toxin type A
A 2-year open-label study of botulinum toxin type B in botulinum toxin type A resistant/responsive cervical dystonia patients (AN072-401 EU/CD)
Is treatment of cervical dystonia patients with botulinum toxin type B affected by a previous response to a botulinum toxin type A? Analysis of a long-term open-label study (AN072-401 EU/CD)
Functional and clinical changes in spastic patients treated with Botulinum Toxin in the upper limb
Botulinum toxin type A (Botox) versus botulinum toxin type B (Myobloc) in subjects with cervical dystonia: A comparison of the frequency of xerostomia and dysphagia (AN072-402 EU/CD)
Botulinum toxin B (NeuroBloc®) dosing: Experience from clinical studies
Comorbidity in focal dystonia and effect of botulinum toxin treatment
Efficacy of botulinum toxin in treatment of spasmodic dysphonia
Treatment of blepharospasm with Dysport® in the Siberian District Medical Center of Roszdrav
Treatment of cervical dystonia with Dysport® in the Siberian District Medical Center of Roszdrav
Botulinum toxin treatment of cervical dystonia supported by imaging procedures—A new method of examination for laterocollis
A meta-analysis of spasticity and pain: Implications for botulinum toxin treatment
Motor disorders: Evidence-based review of the use of botulinum toxins
Botulinum toxin in treatment of axial dystonia
Long-term effects of botulinum toxin A in a cerebral palsy cohort
Role of Botulinum Toxin therapy (BT2) in managing hip flexor spasticity
Effect of treatment with botulinum toxin type A (Dysport®) on health-related quality of life in patients with equinovarus deformity after stroke
Efficacy of Dysport® (Botulinum toxin type A) for the treatment of cervical dystonia: A multicenter, randomized, double-blind, placebo-controlled phase III study
CT-guided BoNT-A injection of longus colli muscle in anterocollis patients without anterior shift
Focal myositis, a novel side effect of BoNT-A in cervical dystonia
Longitudinal experience with a Chinese type A botulinum toxin for the treatment of focal dystonia and hemifacial spasm
Experience of treating cervical dystonia with dysport in the Kazan center of movement disorders
An electrophysiological method to define the treatment with botulinum toxin in neurogenic dysphagias with cricopharyngeal dysfunction
Efficacy of repeated injections of Botulinum Toxin-A in patients with overactive bladder and idiopathic detrusor overactivity
The effects of repeated dosing of botulinum toxin type B (neurobloc®) in patients with cervical dystonia previously naïve to botulinum toxin: An open-label extension study (AN072-402 EU/CD)
High doses of NT 201 (xeomin®) do not alter gastro-intestinal motility
Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory detrusor overactivity
Gastrointestinal tract
Differentiated botulinum toxin treatment of sialorrhea in 15 patients suffering from Parkinson's disease, MSA, PSP, and brain injury in early childhood
The lowest effective dose of botulinum toxin in detrusor sphincter dyssynergia
Effects of botulinum toxin type A on histamine-induced itch and vasomotor responses in human skin
Remission of hair loss and induction of hair regrowth by botulinum neurotoxin A in mice
Anhidrotic effect of intradermal injections of botulinum toxin—A comparison of different products and concentrations
Bilateral forearm intravenous regional anesthesia (IVRA) with prilocaine for botulinum toxin treatment of palmar hyperhidrosis
Treatment of Pachonychia congenita and Epidermolysis bullosa simplex with plantar injections of botulinum toxin
BOTOX for pelvic floor dysfunction
Botulinum toxin to treat parotid saliva retention after transient postoperative Stenon's duct occlusion
Perioperative use of botulinum toxins
Efficacy and safety of Myobloc in headache prophylaxis: A retrospective observation
Myobloc: An answer to 25-years battle with tics?
Botulinum toxin type A in the treatment of chronic migraine and chronic tension-type headache
Inhibition of exocytotic activity in human mast cell line 1 by clostridial neurotoxin light chains
Botulinum toxin A for the treatment of ulcer caused by oro-mandibular dyskinesia in a patient with a vegetative state
Botulinum toxin A and casting for the functionality of paretic arm in children with obstetrical upper brachial plexus palsy
Future indications for botulinum toxin (BoNT)
Success and failure of preventative migraine treatment with botulinum toxin type A: Association with a novel classification of migraine headache
Central effects of BoNT
Ultrasound-guided injection of the psoas muscle with Botulinum Toxin A: Novel approach to treating chronic low back pain
Engineered toxins: New therapeutics
Treatment of spasmodic entropion with botulinum toxin
Botulinum toxin treatment of low back pain and fibromyalgia
Pathogenicity of botulinum C·D mosaic toxins in animals
Intra-articular botulinum toxin A for osteoarticular pain
Process development and pilot-scale production of therapeutic antisera against botulinum toxin type A and B
Botulinum neurotoxin serotype A: A new tool for inflammatory and neuropathic pain
Botulinum toxin in the treatment of sialorrhea
Recombinant antibody potently neutralizes types A, B, and E botulinum neurotoxins by a clearance-driven mechanism
Acute facial palsy (Bell's palsy): A new indication for botulinum toxin?
Safety and efficacy of Myobloc® (botulinum toxin type B) for sialorrhea in Parkinson's disease (PD) patients
Role of botulinum toxin type A or B in the complex, multimodality treatment of neck and back pain. Experience on a series of 490 patients
Have botulinum toxins type A and type B a role in the management of Parkinson's Disease?
Randomised study of botulinum toxin type A (BoNT/A) in the treatment of chronic tension type headache
The use of botulinum toxin type A (BoNT/A) as an adjunctive treatment modality for phonic tics on a series of 30 patients affected with tourette's syndrome (TS)
Optimization of a functional paramagnetic bead-based electrochemiluminescence assay for botulinum toxins A and B
A new BoNT/B subtype detected from infant botulism in Japan